Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation ((18)F-FDG, (64)Cu-ATSM and (18)F-FLT) in a Dog with Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2016 Feb 9

PMID 26854160

Citations 1

Authors

Kamilla Westarp Zornhagen

Malene M Clausen

Anders E Hansen

Ian Law

Fintan J McEvoy

Svend A Engelholm

Andreas Kjaer

Annemarie T Kristensen

Affiliations

Soon will be listed here.

Abstract

Glycolysis, hypoxia, and proliferation are important factors in the tumor microenvironment contributing to treatment-resistant aggressiveness. Imaging these factors using combined functional positron emission tomography and computed tomography can potentially guide diagnosis and management of cancer patients. A dog with fibrosarcoma was imaged using (18)F-FDG, (64)Cu-ATSM, and (18)F-FLT before, during, and after 10 fractions of 4.5 Gy radiotherapy. Uptake of all tracers decreased during treatment. Fluctuations in (18)F-FDG and (18)F-FLT PET uptakes and a heterogeneous spatial distribution of the three tracers were seen. Tracer distributions partially overlapped. It appears that each tracer provides distinct information about tumor heterogeneity and treatment response.

Citing Articles

The Importance of the Tumor Microenvironment and Hypoxia in Delivering a Precision Medicine Approach to Veterinary Oncology.

Gray M, Meehan J, Turnbull A, Martinez-Perez C, Kay C, Pang L Front Vet Sci. 2020; 7:598338.

PMID: 33282935 PMC: 7688625. DOI: 10.3389/fvets.2020.598338.

References

Hoeben B, Troost E, Span P, Van Herpen C, Bussink J, Oyen W . 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med. 2013; 54(4):532-40. DOI: 10.2967/jnumed.112.105999. View

Ballegeer E, Forrest L, Jeraj R, Mackie T, Nickles R . PET/CT following intensity-modulated radiation therapy for primary lung tumor in a dog. Vet Radiol Ultrasound. 2006; 47(2):228-33. DOI: 10.1111/j.1740-8261.2006.00132.x. View

Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A . Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997; 38(7):1155-60. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Clausen M, Hansen A, Lundemann M, Hollensen C, Pommer T, Munck Af Rosenschold P . Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study. Radiat Oncol. 2014; 9:228. PMC: 4203925. DOI: 10.1186/s13014-014-0228-0. View

Bradshaw T, Yip S, Jallow N, Forrest L, Jeraj R . Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy. Int J Radiat Oncol Biol Phys. 2014; 89(2):399-405. PMC: 4041912. DOI: 10.1016/j.ijrobp.2014.02.016. View

Okada M, Shimono T, Komeya Y, Ando R, Kagawa Y, Katsube T . Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions. Ann Nucl Med. 2009; 23(4):349-54. DOI: 10.1007/s12149-009-0246-4. View

Bowen S, Chappell R, Bentzen S, Deveau M, Forrest L, Jeraj R . Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: an exploratory study. Radiother Oncol. 2012; 105(1):41-8. PMC: 3489967. DOI: 10.1016/j.radonc.2012.05.002. View

Hawkins D, Schuetze S, Butrynski J, Rajendran J, Vernon C, Conrad 3rd E . [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005; 23(34):8828-34. DOI: 10.1200/JCO.2005.01.7079. View

10.

Wahl R, Jacene H, Kasamon Y, Lodge M . From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50 Suppl 1:122S-50S. PMC: 2755245. DOI: 10.2967/jnumed.108.057307. View

11.

Jensen M, Erichsen K, Bjorkling F, Madsen J, Jensen P, Hojgaard L . Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PLoS One. 2010; 5(9):e12965. PMC: 2945761. DOI: 10.1371/journal.pone.0012965. View

12.

Hawkins D, Conrad 3rd E, Butrynski J, Schuetze S, Eary J . [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer. 2009; 115(15):3519-25. PMC: 2716419. DOI: 10.1002/cncr.24421. View

13.

Patz Jr E, Lowe V, Hoffman J, Paine S, Burrowes P, Coleman R . Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology. 1993; 188(2):487-90. DOI: 10.1148/radiology.188.2.8327702. View

14.

Been L, Suurmeijer A, Cobben D, Jager P, Hoekstra H, Elsinga P . [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging. 2004; 31(12):1659-72. DOI: 10.1007/s00259-004-1687-6. View

15.

Weber W, Wieder H . Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging. 2006; 33 Suppl 1:27-37. DOI: 10.1007/s00259-006-0133-3. View

16.

Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T . Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992; 33(11):1972-80. View

17.

Harris A . Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2(1):38-47. DOI: 10.1038/nrc704. View

18.

Rodal J, Rusten E, Sovik A, Skogmo H, Malinen E . Functional imaging to monitor vascular and metabolic response in canine head and neck tumors during fractionated radiotherapy. Acta Oncol. 2013; 52(7):1293-9. DOI: 10.3109/0284186X.2013.812800. View

19.

Boellaard R, ODoherty M, Weber W, Mottaghy F, Lonsdale M, Stroobants S . FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2009; 37(1):181-200. PMC: 2791475. DOI: 10.1007/s00259-009-1297-4. View

20.

Lewis J, McCarthy D, McCarthy T, Fujibayashi Y, Welch M . Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med. 1999; 40(1):177-83. View